Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 0069-4031

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 0069-4031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Doxorubicin 01)

FDA Label Image

Figure 1 (Doxorubicin 02)

This text appears to contain information about hazard ratios from various trials comparing different treatments, such as Doxo-based treatments in comparison to CMF. It seems to include data from NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden, BCGA, NSABC Israel, BR0283, Austrian BCSG 3, and other studies. Additionally, it mentions the boundary of non-inferiority with CMF at a specific ratio.*

FDA Label Image

Figure 2 (Doxorubicin 03)

FDA Label Image

Logo (Doxorubicin 04)

FDA Label Image

Logo (Doxorubicin 04a)

FDA Label Image

Principal Display Panel (10 mg/5 mL ONCO-TAIN® Label)

This text contains information about a hazardous drug called DOXOrubicin Hydrochloride Injection, which is a single-dose vial prescription for intravenous use only. It is recommended to discard any unused portion, store refrigerated between 2°C and 8°C (36°F and 46°F), and protect from light. The recommended dosage is 10 mg/5 mL (2 mg/ml). The label mentions the manufacturer as Qilu Pharmaceutical Co., Ltd in New York, NY.*

FDA Label Image

Principal Display Panel (10 mg/5 mL ONCO-TAIN® Carton)

This text is a detailed label for a medication called DOXOrubicin Hydrochloride Injection. It includes important information such as dosage, storage instructions, warning about being a hazardous drug, and pharmaceutical details. The medication is intended for intravenous use only and should be stored refrigerated and protected from light. Each milliliter contains 2 mg of DOXOrubicin hydrochloride and 9 mg of sodium chloride. It is recommended to refer to the prescribing information for the correct dosage and usage instructions.*

FDA Label Image

Principal Display Panel (20 mg/10 mL ONCO-TAIN® Label)

This is a description of a medication labeled NDC 0069-4031-12, which is likely an oncologic solution called DOXOrubicin Hydrochloride Injection. It advises to store the medication refrigerated between 2°C and 8°C and for intravenous use only. It recommends referring to the prescribing information for dosage instructions. The product is distributed by Pfizer Labs and contains 20 mg/10 mL (2 mg/ml). The text also mentions a warning about the hazardous nature of the drug.*

FDA Label Image

Principal Display Panel (20 mg/10 mL ONCO-TAIN® Carton)

This is a drug label for a medication called "IDOXOrubicin Hydrochloride Injection" with a concentration of 20 mg/10 mL. It is intended for intravenous use only and should be stored refrigerated between 2°C and 8°C (36°F and 46°F). The solution contains 2 mg of doxorubicin hydrochloride (equivalent to 1.917 mg of doxorubicin) and 9 mg of sodium chloride per milliliter, with a pH adjusted to 3.0. The text mentions discarding unused portions and includes dosage instructions. The medication is distributed by Pfizer under the brand Novaplus.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.